HR

Hardik Ramjibhai Patel

Active Director Director DIN 00470177
DIN 00470177 First appointment Jan 2006 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 2 historical roles
Total affiliations 5 Since Jan 2006
Shareholding value •••• Premium profile

About Hardik Ramjibhai Patel

Data last updated:

Hardik Ramjibhai Patel is a Director at Alpha Therapeutics Private Limited (since 2006), Director at Airmed Exim Private Limited (since 2014) and Director at Oximed Technologies Confederation (since 2024). The companies operate in Healthcare and Chemicals. The 2 current companies with reported revenue have a combined latest revenue of ₹21.39 Cr; the largest is Alpha Therapeutics Private Limited at ₹19.74 Cr (FY 2025). Earlier, Hardik Ramjibhai Patel was a Director at Sysmed Exim Private Limited (2014–2017) and Director at Alpha Transfusion Private Limited (from 2007).

DIN 00470177
Primary Designation Director
Industry Healthcare
First Appointment 17 Jan 2006
Oldest Company Age 20 yrs
Largest company Alpha Therapeutics Private Limited · ₹19.74 Cr (FY 2025)
Combined revenue ₹21.39 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Alpha Therapeutics Private Limited U24230GJ2006PTC047526
Director17 Jan 20062006₹19.74 Cr (FY 2025)Active
Airmed Exim Private Limited U33111GJ2014PTC080359
Director04 Aug 20142014₹1.65 Cr (FY 2017)Under Process Of Striking Off
Oximed Technologies Confederation U88900GJ2024NPL153205
Director05 Jul 20242024Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sysmed Exim Private Limited U51900PB2014PTC038818
Director25 Sep 20142014₹126 Cr (FY 2024)Active
Alpha Transfusion Private Limited U33112GJ2007PTC052036
Director24 Oct 20072007Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Alpha Therapeutics Private Limited
Airmed Exim Private Limited
Alpha Transfusion Private Limited
Oximed Technologies Confederation
Premium access

Shareholding and investment profile for Hardik Ramjibhai Patel

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hardik Ramjibhai Patel

Hardik Ramjibhai Patel currently holds 3 directorships: Alpha Therapeutics Private Limited (Director, since 17 Jan 2006, revenue ₹19.74 Cr (FY 2025)); Airmed Exim Private Limited (Director, since 04 Aug 2014, revenue ₹1.65 Cr (FY 2017)); Oximed Technologies Confederation (Director, since 05 Jul 2024).

Hardik Ramjibhai Patel was first appointed on 17 Jan 2006 as Director at Alpha Therapeutics Private Limited. The most recent appointment on record is 05 Jul 2024 at Oximed Technologies Confederation.

The 2 current companies of Hardik Ramjibhai Patel that report revenue have a combined latest revenue of ₹21.39 Cr: Alpha Therapeutics Private Limited ₹19.74 Cr (FY 2025); Airmed Exim Private Limited ₹1.65 Cr (FY 2017).

Hardik Ramjibhai Patel held 2 earlier board appointments: Sysmed Exim Private Limited (Director, 25 Sep 2014 to 16 Dec 2017); Alpha Transfusion Private Limited (Director, from 24 Oct 2007).

The current boards of Hardik Ramjibhai Patel's companies include Deepaben Ramjibhai Patel (Alpha Therapeutics Private Limited), Ramjibhai Punjabhai Patel (Alpha Therapeutics Private Limited), Vallari Hardikbhai Patel (Alpha Therapeutics Private Limited), Dhaval Subhash Patel (Airmed Exim Private Limited), Ambalal Somabhai Patel (Oximed Technologies Confederation), Kirtikumar Jayantilal Patel (Oximed Technologies Confederation), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available